This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HealthEquity (HQY) Q2 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYNH or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?
CIVI or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CIVI vs. HQY: Which Stock Is the Better Value Option?
SYNH vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?
NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Is HealthEquity (HQY) a Great Growth Stock?
by Zacks Equity Research
HealthEquity (HQY) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Can HealthEquity (HQY) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
HealthEquity (HQY) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
HealthEquity (HQY) Looks Good: Stock Adds 11.5% in Session
by Zacks Equity Research
HealthEquity (HQY) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.
Medical Stocks Reporting Q4 Earnings on Feb 6: CNC, WCG, HQY
by Zacks Equity Research
Medical stocks' fourth-quarter results are likely to benefit from higher membership, increase in premium, partly offset by high costs.
Should You Buy HealthEquity (HQY) Ahead of Earnings?
by Zacks Equity Research
HealthEquity (HQY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Looking for a Growth Stock? Why It is Time to Focus on HealthEquity (HQY)
by Zacks Equity Research
HealthEquity (HQY) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
ICON Public Limited (ICLR) Rises: Stock Adds 6.3% in Session
by Zacks Equity Research
ICON Public Limited Company (ICLR) shares rose over 6% in the last trading session.
Why HealthEquity (HQY) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity Inc (HQY) reported earnings of 7 cents per share in the fourth quarter of 2016, higher than the Zacks Consensus Estimate of 5 cents.
Top 5 Medical Service Stocks to Buy
by Brian Hamilton
The Medical sector is one of the top performing sectors for Q3 2015, and it is expected to be a top performer in Q4 2015 too.